Related Experiment Video
Updated: Aug 10, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Metabolism of furazolidone: alternative pathways and modes of toxicity in different cell lines
I De Angelis1, L Rossi, J Z Pedersen
1Istituto Superiore di Sanità, Laboratorio di Tossicologia Comparata ed Ecotossicologia, Rome, Italy.
Abstract:
1. The metabolism and cytotoxicity of the antimicrobial nitrofuran drug furazolidone have been studied in Caco-2, HEp-2 and V79 cell lines. Free radical production, metabolite pattern, formation of bound residues, inhibition of cellular replication and protection by the antioxidant glutathione were compared for the three cell lines. 2. All three cell lines produced the same nitro-anion radical with similar kinetics. Little further metabolic breakdown was observed in V79 cells, whereas Caco-2 and HEp-2 cells showed extensive degradation of furazolidone, but with different end patterns. 3. Under hypoxic conditions, the colony-forming ability was extensively impaired in HEp-2 cells whereas the other two cell lines were less affected, suggesting that irreversible damage to DNA occurred prevalently in HEp-2 cells. In V79 cells the absence of oxygen caused a 25-fold increase in the formation of protein-bound residues. 4. Brief exposure to furazolidone caused a 50% loss of endogenous glutathione in Caco-2 cells, but no loss could be detected in V79 and HEp-2 cells. Consistently, when glutathione was depleted by buthionine-[S,R]-sulphoximine (BSO) and diethylmaleate (DEM) treatment, the viability of V79 and HEp-2 cells was minimally affected by furazolidone, whereas that of Caco-2 cells was substantially reduced. 5. It is concluded that the cytotoxicity of furazolidone in these cell lines can be exerted by a number of different mechanisms, possibly related to different metabolic pathways. The cytotoxicity of nitrofuran drugs, therefore, cannot be ascribed to a single toxic intermediate, but in Caco-2 cells furazolidone is extensively metabolized and detoxified by GSH, in V79 is only partially activated and then bound to proteins, whereas in HEp-2, once activated, may react with DNA.
Insights
Furazolidone
Area of Science:
- Cellular biology
- Pharmacology
- Toxicology
Background:
- Furazolidone is an antimicrobial nitrofuran drug.
- Understanding its cellular metabolism and cytotoxicity is crucial for drug safety.
- Variations in cellular response to drugs can impact efficacy and side effects.
Purpose of the Study:
- To investigate the metabolism and cytotoxicity of furazolidone across different cell lines.
- To compare free radical production, metabolite patterns, and cellular damage mechanisms.
- To assess the role of glutathione in furazolidone's protective effects.
Main Methods:
- Comparative study using Caco-2, HEp-2, and V79 cell lines.
- Analysis of free radical production, metabolite profiles, and bound residue formation.
- Assessment of cellular replication inhibition, colony-forming ability under hypoxia, and glutathione levels.
Main Results:
- All cell lines produced similar nitro-anion radicals; metabolic breakdown varied significantly.
- HEp-2 cells showed impaired colony-forming ability under hypoxia, suggesting DNA damage.
- Caco-2 cells exhibited glutathione depletion and reduced viability upon furazolidone exposure, unlike V79 and HEp-2 cells.
Conclusions:
- Furazolidone's cytotoxicity is mediated by diverse mechanisms linked to specific metabolic pathways.
- Cellular response to furazolidone is cell-type dependent, not attributable to a single toxic intermediate.
- Caco-2 cells detoxify furazolidone via glutathione, V79 cells form protein-bound residues, and HEp-2 cells may experience DNA-related damage.
Related Concept Videos
Drug Biotransformation: Overview
Drug Metabolism: Phase II Reactions
Drug Biotransformation: Overview
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

